Beyond ADCs: Exploring Novel Therapeutic Opportunities in Platinum Resistant Ovarian Cancer, an Industry Supported Symposium

Activity Overview

The GOG Foundation, Inc. and GOG Partners welcome gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to attend the Beyond ADCs: Exploring Novel Therapeutic Opportunities in Platinum Resistant Ovarian Cancer, an Industry Supported Symposium presented at the WAGO 2025 Annual Meeting on Friday, June 20, 2025. This educational symposium will focus on innovative and emerging treatment options for patients with advanced, platinum-resistant high-grade epithelial ovarian cancer. While ADCs have transformed the landscape, the conversation is now evolving beyond these therapies. This session will explore new and recently approved treatment opportunities, including novel mechanisms of action and strategic therapeutic combinations. Faculty will critically examine recent clinical trial data, taking a deeper look at progression-free survival (PFS) and overall survival (OS) curves, and how to interpret these metrics in a clinically meaningful way. Through expert insights and collaborative dialogue, attendees will be better equipped to apply data-driven strategies to improve patient outcomes.
The GOG Foundation, Inc. is grateful for our commercial supporter for this symposium: Corcept Therapuetics
 

Target Audience

Gynecologic and medical oncologists, oncology researchers, clinical trial coordinators, advanced practice providers, and other healthcare professionals involved in the management of ovarian cancer.

Learning Objectives

Upon completion of the activities in this series, learners will demonstrate increased knowledge regarding:
  • Identify Emerging Therapies: Review new and recently approved therapies for platinum-resistant ovarian cancer beyond antibody-drug conjugates.
  • Interpret Efficacy Data Critically: Analyze and interpret PFS/OS data and clinical trial endpoints, focusing on underlying statistics and their real-world implications for patients.
  • Examine the Competitive Landscape: Understand where novel therapies fit into the current and future treatment paradigms for ovarian cancer.
  • Foster Clinical Dialogue: Promote thoughtful discussion among oncologists and researchers on implementing these new strategies in clinical practice and research.

Agenda

Beyond ADCs: Exploring Novel Therapeutic Opportunities in Platinum Resistant Ovarian Cancer, an Industry Supported Symposium presented at the WAGO 2025 Annual Meeting

 
11:55 am – 12:00 pm MT
Welcome and Introductions All Faculty
12:00 pm – 12:15 pm MT
The Evolving Landscape of Platinum-Resistant Ovarian Cancer Dana Chase, MD, UCLA Medical Center, Los Angeles, CA
12:15 pm – 12:30 pm MT
Beyond ADCs: Novel Agents and Mechanisms on the Horizon Katherine Fuh, MD, PhD, University of California San Francisco (UCSF), San Francisco, CA
12:30 pm – 12:45 pm MT
Digging into the Data: Making Sense of PFS/OS Curves Debra Richardson, MD, Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK
12:45 pm – 1:05 pm MT
Panel Discussion: Real-World Implications and What’s Next All Faculty
1:05 pm – 1:15 pm MT
Audience Q&A All Faculty
1:15 pm – 1:20 pm MT
Closing Remarks All Faculty
Continuing Education
In support of improving patient care, this activity has been planned and implemented by The GOG Foundation, Inc. (GOG).
Accreditation Statement
The GOG Foundation, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Continuing Medical Education for physicians.
AMA PRA Category 1 Credits™
The GOG Foundation, Inc. designates this in-person activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Method of Participation
There are no fees for participating in and receiving CME credit for this activity. Participants must: 1) read the educational objectives and faculty disclosures; 2) attend the educational activity; 3) complete the online evaluation that will be sent to all registered participants who provide a valid email address and attend the activity.
Participants who complete the educational activity and evaluation will receive a certificate of credit.
Disclosure Declaration
In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any ineligible company *(formally known as commercial interests). All Committee/Planning/Faculty members were required to disclose all financial relationships and speakers were required to disclose any financial relationship as it pertains to the content of the presentations. All relevant financial relationships listed for these individuals have been mitigated to ensure a bias-free presentation. Please see the faculty disclosure list for detailed information.
Faculty Disclosures
  • Dana Chase, MD, UCLA Medical Center, Los Angeles, CA
  • Katherine Fuh, MD, PhD, University of California San Francisco (UCSF), San Francisco, CA
  • Debra Richardson, MD, Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK